探索COVID-19疫苗接种后雷诺现象的危险因素
本研究通过检索PubMed、EMBASE和Web of Science(2020年1月1日至2024年3月19日),纳入5篇病例报告和1篇病例系列(共24例接种COVID-19疫苗后出现雷诺现象的患者),分析其危险因素。结果发现女性占70.83%、87.5%有雷诺现象病史或可能易感因素,疫苗剂次与发病无关,75%接受了mRNA疫苗。作者认为研究设计未控制且样本量小,无法确定因果关系,但医生应保持警惕。
要点
- 接种COVID-19疫苗后雷诺现象在女性中更常见(70.83% vs 男性29.17%)。
- 87.5%(21/24)的患者有雷诺现象病史或可能易感因素。
- 疫苗剂次与雷诺现象发生无关(第1剂45% vs 第2剂30% vs 第3剂25%)。
核心结论
- 由于研究设计未控制且样本量小,偏倚风险增加,无法将雷诺现象与COVID-19疫苗接种进行因果推断。
- 这些少数病例可能独立于疫苗接种而发生。
- 然而,医生仍应对COVID-19疫苗接种后出现的雷诺现象保持警惕,尤其是随着接种人数持续增加。
研究设计与样本
- 检索PubMed、EMBASE和Web of Science从2020年1月1日至2024年3月19日的文献。
- 纳入有临床相关发现的文章,具体为病例报告和病例系列。
- 排除会议摘要、社论、预印本以及不专门涉及COVID-19疫苗接种的文章。
- 最终纳入6篇文章,包括5篇病例报告和1篇病例系列,共24例接种后雷诺现象患者。
主要发现
- 接种COVID-19疫苗后雷诺现象在女性中较男性更常见(70.83% vs 29.17%)。
- 87.5%(21/24)的接种后雷诺现象患者有雷诺现象病史或可能易感因素。
- 在有详细疫苗接种信息的患者(n=20)中,疫苗剂次与雷诺现象发生无关(第1剂45% vs 第2剂30% vs 第3剂25%)。
- 75%(15/20)的雷诺现象患者接种的是mRNA疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究设计未控制且样本量小,导致偏倚风险增加。
- 无法将雷诺现象与COVID-19疫苗接种进行因果推断。
- 这些少数病例可能独立于疫苗接种而发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Raynaud's phenomenon (RP) has recently been observed in recipients of the COVID-19 vaccine. It is unclear whether RP is directly caused by the COVID-19 vaccine. This study aims to investigate the potential causation between RP and COVID-19 vaccination. METHODS: In this study, we searched PubMed, EMBASE, and Web of Science from January 1, 2020, to March 19, 2024. We included the articles with clinical related findings, specifically case reports and case series. Conference abstracts, editorial publications, preprint, and those not specifically related to COVID-19 vaccination are excluded. The refined selection process aimed to ensure a focused and clinically relevant analysis of the association between RP and COVID-19 vaccination. RESULTS: A total of six articles were ultimately included in this study, comprising five case reports and one case series involving 24 patients with RP after vaccination. Baseline characteristics of the studies showed the RP post COVID-19 vaccination frequently occurred with females compared to males (70.83 vs. 29.17 %). Of the patients with RP post COVID-19 vaccination, 87.5 % (21/24) had either a history or possible predisposing factors of RP. Among the patients with detailed information of vaccination (n = 20), the number of vaccine doses was not related to RP development (45 % (1st) vs. 30 % (2nd) vs. 25 % 3rd dose). For types of vaccine, 75 % of RP were found to have received the administration of mRNA vaccine (15/20). CONCLUSION: The risk of bias was increased due to the uncontrolled study designs and small sample size, making it impossible to attribute causation between RP and COVID-19 vaccination. These few cases may have occurred independently of vaccination. However, physicians should still remain vigilant for RP following COVID-19 vaccination, particularly as the number of vaccinated individuals continues to rise.
引用
- Ho TC, Chuang SC, Hung KC, et al. Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination. Vaccine. 2024. PMID: 39467409. doi:10.1016/j.vaccine.2024.126470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。